Insights into immuno-oncology drug development landscape with focus on bone metastasis
Bone is among the main sites of metastasis in breast, prostate and other major cancers. Bone metastases remain incurable causing high mortality, severe skeletal-related effects and decreased quality of life. Despite the success of immunotherapies in oncology, no immunotherapies are approved for bone...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121878/full |
| _version_ | 1797786800127737856 |
|---|---|
| author | Tiina E. Kähkönen Jussi M. Halleen Gary MacRitchie Ronnie M. Andersson Jenni Bernoulli |
| author_facet | Tiina E. Kähkönen Jussi M. Halleen Gary MacRitchie Ronnie M. Andersson Jenni Bernoulli |
| author_sort | Tiina E. Kähkönen |
| collection | DOAJ |
| description | Bone is among the main sites of metastasis in breast, prostate and other major cancers. Bone metastases remain incurable causing high mortality, severe skeletal-related effects and decreased quality of life. Despite the success of immunotherapies in oncology, no immunotherapies are approved for bone metastasis and no clear benefit has been observed with approved immunotherapies in treatment of bone metastatic disease. Therefore, it is crucial to consider unique features of tumor microenvironment in bone metastasis when developing novel therapies. The vicious cycle of bone metastasis, referring to crosstalk between tumor and bone cells that enables the tumor cells to grow in the bone microenvironment, is a well-established concept. Very recently, a novel osteoimmuno-oncology (OIO) concept was introduced to the scientific community. OIO emphasizes the significance of interactions between tumor, immune and bone cells in promoting tumor growth in bone metastasis, and it can be used to reveal the most promising targets for bone metastasis. In order to provide an insight into the current immuno-oncology drug development landscape, we used 1stOncology database, a cancer drug development resource to identify novel immunotherapies in preclinical or clinical development for breast and prostate cancer bone metastasis. Based on the database search, 24 immunotherapies were identified in preclinical or clinical development that included evaluation of effects on bone metastasis. This review provides an insight to novel immuno-oncology drug development in the context of bone metastasis. Bone metastases can be approached using different modalities, and tumor microenvironment in bone provides many potential targets for bone metastasis. Noting current increasing interest in the field of OIO, more therapeutic opportunities that primarily target bone metastasis are expected in the future. |
| first_indexed | 2024-03-13T01:13:57Z |
| format | Article |
| id | doaj.art-c880064a4f1d483585bc6bdebaca425b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T01:13:57Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c880064a4f1d483585bc6bdebaca425b2023-07-05T15:06:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.11218781121878Insights into immuno-oncology drug development landscape with focus on bone metastasisTiina E. Kähkönen0Jussi M. Halleen1Gary MacRitchie2Ronnie M. Andersson3Jenni Bernoulli4OncoBone Ltd, Oulu, FinlandOncoBone Ltd, Oulu, Finland1stOncology, BioSeeker Group AB, Stockholm, Sweden1stOncology, BioSeeker Group AB, Stockholm, SwedenUniversity of Turku, Institute of Biomedicine, Turku, FinlandBone is among the main sites of metastasis in breast, prostate and other major cancers. Bone metastases remain incurable causing high mortality, severe skeletal-related effects and decreased quality of life. Despite the success of immunotherapies in oncology, no immunotherapies are approved for bone metastasis and no clear benefit has been observed with approved immunotherapies in treatment of bone metastatic disease. Therefore, it is crucial to consider unique features of tumor microenvironment in bone metastasis when developing novel therapies. The vicious cycle of bone metastasis, referring to crosstalk between tumor and bone cells that enables the tumor cells to grow in the bone microenvironment, is a well-established concept. Very recently, a novel osteoimmuno-oncology (OIO) concept was introduced to the scientific community. OIO emphasizes the significance of interactions between tumor, immune and bone cells in promoting tumor growth in bone metastasis, and it can be used to reveal the most promising targets for bone metastasis. In order to provide an insight into the current immuno-oncology drug development landscape, we used 1stOncology database, a cancer drug development resource to identify novel immunotherapies in preclinical or clinical development for breast and prostate cancer bone metastasis. Based on the database search, 24 immunotherapies were identified in preclinical or clinical development that included evaluation of effects on bone metastasis. This review provides an insight to novel immuno-oncology drug development in the context of bone metastasis. Bone metastases can be approached using different modalities, and tumor microenvironment in bone provides many potential targets for bone metastasis. Noting current increasing interest in the field of OIO, more therapeutic opportunities that primarily target bone metastasis are expected in the future.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121878/fullcancerbone metastasisimmuno-oncologyosteoimmuno-oncologyimmunotherapiesdrug development |
| spellingShingle | Tiina E. Kähkönen Jussi M. Halleen Gary MacRitchie Ronnie M. Andersson Jenni Bernoulli Insights into immuno-oncology drug development landscape with focus on bone metastasis Frontiers in Immunology cancer bone metastasis immuno-oncology osteoimmuno-oncology immunotherapies drug development |
| title | Insights into immuno-oncology drug development landscape with focus on bone metastasis |
| title_full | Insights into immuno-oncology drug development landscape with focus on bone metastasis |
| title_fullStr | Insights into immuno-oncology drug development landscape with focus on bone metastasis |
| title_full_unstemmed | Insights into immuno-oncology drug development landscape with focus on bone metastasis |
| title_short | Insights into immuno-oncology drug development landscape with focus on bone metastasis |
| title_sort | insights into immuno oncology drug development landscape with focus on bone metastasis |
| topic | cancer bone metastasis immuno-oncology osteoimmuno-oncology immunotherapies drug development |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1121878/full |
| work_keys_str_mv | AT tiinaekahkonen insightsintoimmunooncologydrugdevelopmentlandscapewithfocusonbonemetastasis AT jussimhalleen insightsintoimmunooncologydrugdevelopmentlandscapewithfocusonbonemetastasis AT garymacritchie insightsintoimmunooncologydrugdevelopmentlandscapewithfocusonbonemetastasis AT ronniemandersson insightsintoimmunooncologydrugdevelopmentlandscapewithfocusonbonemetastasis AT jennibernoulli insightsintoimmunooncologydrugdevelopmentlandscapewithfocusonbonemetastasis |